Professor Dr Christoph Huber is the former chair of Hematology and Oncology at the University of Mainz (JGU). He is an expert in tumor and transplantation immunology and a co-founder of the biotech companies Ganymed Pharmaceuticals and BioNtech. Christoph Huber has held many national and international roles at various research organizations and regulatory agencies.

Christof von Kalle

Professor Dr Christof von Kalle chairs the board of directors at the National Center for Tumor Diseases (NCT) in Heidelberg and is head of the Translational Oncology department at the German Cancer Research Center (DKFZ). Christof von Kalle was trained in internal medicine, hematology/oncology and molecular biology. He has made significant contributions towards the development of innovative strategies for gene therapy for cancer and severe inherited diseases. He is the coordinator of the national consortium Innovative Genetic Treatment of Immunodeficiencies (iGene) and is the work package leader in several EU-funded projects (Clinigene, PERSIST, E-rare), as well as a member of several scientific advisory boards.

Hans-Jochem Kolb

Professor Dr Hans-Jochem Kolb is a highly recognized specialist in hematological oncology, cellular immunotherapy and bone marrow/stem cell transplantation. He received his Medical Degree at the Universities of Freiburg, Innsbruck, Vienna and Munich. While he recently retired as a Professor of Medicine and a senior physician at the University of Munich (LMU), he remains a visiting professor and consultant at universities in the USA, Brazil and Germany. Hans-Jochem Kolb has won several prestigious awards for his medical and scientific contributions.

Wolf Schmiegel

Professor Dr Wolf Schmiegel is Professor of Medicine at the Ruhr University of Bochum and Head of the Department of Medicine at both the Knappschafts-Krankenhaus and the Department of Gastroenterology/Hepatology at the University Clinics Bergmannsheil. His research interests focus on molecular medicine and the molecular genetics of cancer and the identification of prognostic and predictive markers in digestive cancer. Wolf Schmiegel was Councilor of the United European Gastroenterology Foundation; President of the German Association of Digestive and Metabolic Diseases; Secretary General of the European Society of Digestive Oncology; and President of the National German Cancer Conference. He is a member of numerous European and American societies in the field of oncology and hepatic and digestive diseases.

Iris Löw-Friedrich

Professor Dr Iris Loew-Friedrich MD, is Executive Vice-President Biopharma Development Solutions and Chief Medical Officer, UCB S.A. in Brussels. She is a member of the UCB Executive Committee and provides strategic global leadership for world-wide clinical development; medical affairs; global regulatory affairs and project leadership for UCB’s portfolio of pipeline projects and products. Iris Loew-Friedrich also oversees UCB’s Patient Affairs function, which places a strategic focus on better understanding and improving patient experience.
Iris Loew-Friedrich has held several medical and R&D roles, including Head of Global Projects at BASF Pharma (Ludwigshafen) and Therapeutic Area Head, Rheumatology and Bone Diseases, Hoechst/HMR (Bridgewater). From 2001, she served as a member of the Executive Board and as Head of Global Research and Development for Schwarz Pharma, which UCB acquired in 2006.
Iris Loew-Friedrich received her medical license and her PhD from Frankfurt University in 1985. She is board-certified in internal medicine and holds a professorship (‘außerordentliche Professur’) at Frankfurt University Medical School.